Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?

Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R.

J Clin Psychopharmacol. 2012 Aug;32(4):470-8. doi: 10.1097/JCP.0b013e31825ccde5.

PMID:
22722504
2.

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.

Potkin SG, Keck PE Jr, Segal S, Ice K, English P.

J Clin Psychopharmacol. 2005 Aug;25(4):301-10.

PMID:
16012271
3.

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B.

J Clin Psychiatry. 2011 Oct;72(10):1413-22. doi: 10.4088/JCP.09m05934.

PMID:
21672493
4.

Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.

Sachs GS, Vanderburg DG, Karayal ON, Kolluri S, Bachinsky M, Cavus I.

J Clin Psychiatry. 2012 Nov;73(11):1412-9. doi: 10.4088/JCP.11m07388.

PMID:
23218157
5.

Achieving and sustaining remission in bipolar I disorder with ziprasidone : a post hoc analysis of a 24-week, double-blind, placebo-controlled study.

Pae CU, Masand PS, Mandel FS, O'Gorman C.

Clin Drug Investig. 2012 Nov;32(11):747-54. doi: 10.1007/s40261-012-0009-1.

PMID:
23026845
6.

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.

Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J.

J Psychopharmacol. 2010 Apr;24(4):547-58. doi: 10.1177/0269881108099418. Epub 2008 Dec 12.

PMID:
19074536
7.

A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.

Patkar A, Gilmer W, Pae CU, Vöhringer PA, Ziffra M, Pirok E, Mulligan M, Filkowski MM, Whitham EA, Holtzman NS, Thommi SB, Logvinenko T, Loebel A, Masand P, Ghaemi SN.

PLoS One. 2012;7(4):e34757. doi: 10.1371/journal.pone.0034757. Epub 2012 Apr 24.

8.

Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies.

Stahl S, Lombardo I, Loebel A, Mandel FS.

J Affect Disord. 2010 Apr;122(1-2):39-45. doi: 10.1016/j.jad.2009.06.023. Epub 2009 Jul 17.

PMID:
19616304
9.

Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.

Hirschfeld RM, Weisler RH, Raines SR, Macfadden W; BOLDER Study Group.

J Clin Psychiatry. 2006 Mar;67(3):355-62.

PMID:
16649820
10.

A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.

Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M.

J Clin Psychiatry. 2012 Dec;73(12):1541-7. doi: 10.4088/JCP.12m07670.

PMID:
23290327
11.

Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.

Camm AJ, Karayal ON, Meltzer H, Kolluri S, O'Gorman C, Miceli J, Tensfeldt T, Kane JM.

CNS Drugs. 2012 Apr 1;26(4):351-65. doi: 10.2165/11599010-000000000-00000.

PMID:
22452529
12.

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.

Keck PE Jr, Reeves KR, Harrigan EP; Ziprasidone Study Group.

J Clin Psychopharmacol. 2001 Feb;21(1):27-35.

PMID:
11199944
13.

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.

Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG.

J Clin Psychopharmacol. 2006 Apr;26(2):157-62.

PMID:
16633144
14.
15.
16.

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.

Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M.

J Clin Psychiatry. 2010 Feb;71(2):130-7. doi: 10.4088/JCP.09m05482yel. Epub 2010 Jan 26.

PMID:
20122373
17.

Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania.

Keck PE Jr, Versiani M, Warrington L, Loebel AD, Horne RL.

J Clin Psychiatry. 2009 Jun;70(6):844-51.

PMID:
19573482
18.

Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.

Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R.

J Clin Psychopharmacol. 2008 Feb;28(1):13-20. doi: 10.1097/jcp.0b013e3181618eb4. Erratum in: J Clin Psychopharmacol. 2009 Feb;29(1):38.

PMID:
18204335
19.

The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.

Harvey PD, Endicott JM, Loebel AD.

Bipolar Disord. 2008 Dec;10(8):900-6. doi: 10.1111/j.1399-5618.2008.00634.x.

PMID:
19594505
20.

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.

Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC.

BMC Psychiatry. 2013 May 14;13:138. doi: 10.1186/1471-244X-13-138.

Items per page

Supplemental Content

Write to the Help Desk